Shanghai Junshi Biosciences Co., Ltd.
GPTKB entity
Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Li_Ning
|
| gptkbp:collaboratedWith |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:country |
gptkb:China
|
| gptkbp:developedBy |
COVID-19 antibody therapies
|
| gptkbp:focusesOn |
immuno-oncology
innovative drugs |
| gptkbp:founded |
2012
|
| gptkbp:founder |
gptkb:Li_Ning
|
| gptkbp:hasResearchCenter |
gptkb:Beijing,_China
gptkb:Shanghai,_China gptkb:Suzhou,_China gptkb:San_Francisco,_USA |
| gptkbp:headquartersLocation |
gptkb:Shanghai,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shanghai Junshi Biosciences Co., Ltd.
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
gptkb:toripalimab
|
| gptkbp:numberOfEmployees |
over 2000
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
gptkb:Shanghai_Stock_Exchange |
| gptkbp:stockSymbol |
1877
688180 |
| gptkbp:website |
https://www.junshipharma.com
|
| gptkbp:bfsParent |
gptkb:2171.HK
|
| gptkbp:bfsLayer |
8
|